LETTER
(c 0.80, CHCl3); for S-isomer (>98% ee): [a]D27 +67.7 (c
Synthetic Approach to Nine-Membered Diallylic Amides
2521
CDCl3): d = 143.1, 134.8, 129.5, 128.2, 127.5, 127.3, 57.5,
0.88, CHCl3). Anal. Calcd for C16H21NO2S: C, 65.95; H,
7.26; N, 4.81; S, 11.00. Found: C, 65.55; H, 7.24; N, 4.70; S,
11.52.
47.3, 36.5, 27.8, 22.9, 21.6, 20.9. IR (neat): 2924, 1598,
1450, 1343, 1161, 1092, 848, 817, 659, 593 cm–1. [a]D
25
–98.6 (c 1.31, CHCl3).
Compound 2c: 1H NMR (300 MHz, CDCl3): d = 7.66 (d,
J = 8.1 Hz, 2 H), 7.30 (d, J = 8.1 Hz, 2 H), 5.47–5.24 (m, 3
H), 4.40 (dd, J = 10.2, 3.9 Hz, 1 H), 3.82 (dd, J = 14.2, 4.2
Hz, 1 H), 3.00 (dd, J = 10.2, 9.9 Hz, 1 H), 2.80 (dd, J = 14.2,
11.9 Hz, 1 H), 2.43 (s, 3 H), 2.33–2.28 (m, 1 H), 2.03–1.96
(m, 1 H), 1.91–1.83 (m, 1 H), 1.69 (s, 3 H), 1.67–1.52 (m, 1
H). 13C NMR (75 MHz, CDCl3): d = 143.0, 138.1, 135.9,
132.8, 129.6, 128.4, 127.1, 126.1, 53.2, 45.0, 32.1, 29.4,
25.3, 21.6. IR (neat): 2934, 1319, 1149, 983, 893, 815, 734,
655, 597, 547 cm–1. For R-isomer (>98% ee): [a]D28 –88.8 (c
1.23, CHCl3); for S-isomer (>98% ee): [a]D29 +88.5 (c 1.60,
CHCl3). Anal. Calcd for C16H21NO2S: C, 65.95; H, 7.26; N,
4.81. Found: C, 65.92; H, 7.26; N, 4.68.
Compound 17; 60:40 rotamer ratio (# denotes major,
* denotes minor rotamer signals): 1H NMR (300 MHz,
CDCl3): d = 6.96* (s, 1 H), 6.95# (s, 1 H), 6.76* (s, 1 H),
6.71# (s, 1 H), 6.04# (d, J = 10.2 Hz, 1 H), 5.99–5.96* (m, 1
H), 5.96 (s, 2 H), 5.80–5.73# (m, 1 H), 5.68–5.63* (m, 1 H),
5.23* (d, J = 9.9 Hz, 1 H), 4.62# (dd, J = 4.8, 2.1 Hz, 1 H),
4.04–3.98* (m, 1 H), 3.64# (dd, J = 9.0, 6.0 Hz, 1 H), 3.32–
3.13 (m, 1 H), 2.54–2.37 (m, 1 H), 2.14–1.58 (m, 6 H). 13
C
NMR (75 MHz, CDCl3): d = 167.1*, 167.0#, 148.6*, 148.5#,
147.4#, 147.3*, 132.6#, 132.4*, 129.0, 128.0, 125.8*, 125.0#,
112.7#, 109.8*, 108.0*, 107.3#, 102.1*, 102.0#, 57.0*, 55.3#,
47.0#, 44.8*, 36.6*, 35.6#, 27.6#, 25.3*, 22.7#, 22.1*, 21.0#,
20.2*. IR (neat): 2922, 1631, 1482, 1440, 1374, 1239, 1109,
1035, 932, 863, 732, 617 cm–1. [a]D25 –146.4 (c 0.86,
CHCl3).
Compound 2d: 1H NMR (300 MHz, CDCl3): d = 7.67 (d,
J = 8.1 Hz, 2 H), 7.31 (d, J = 8.1 Hz, 2 H), 5.63 (dddd,
J = 11.4, 11.1, 4.8, 1.2 Hz, 1 H), 5.40–5.24 (m, 3 H), 4.41
(dd, J = 9.9, 3.3 Hz, 1 H), 3.83 (dd, J = 14.1, 4.2 Hz, 1 H),
3.00 (dd, J = 9.9, 9.9 Hz, 1 H), 2.84 (dd, J = 14.1, 11.7 Hz, 1
H), 2.43 (s, 3 H), 2.37–2.30 (m, 1 H), 2.26–2.17 (m, 1 H),
1.77–1.65 (m, 1 H), 1.58–1.45 (m, 1 H). 13C NMR (75 MHz,
CDCl3): d = 143.1, 136.9, 135.8, 131.7, 129.7, 128.8, 127.1,
126.1, 53.4, 44.0, 30.2, 26.6, 21.7. IR (reflection): 3016,
2934, 2869, 1920, 1806, 1661, 1596, 1459, 1347, 988 cm–1.
For R-isomer (>98% ee): [a]D25 –114.2 (c 1.21, CHCl3); for
S-isomer (>98% ee): [a]D26 +118.9 (c 1.97, CHCl3). Anal.
Calcd for C15H19NO2S: C, 64.95; H, 6.90; N, 5.05; S, 11.56.
Found: C, 65.22; H, 7.07; N, 4.92; S, 11.25.
Compound 18: 1H NMR (300 MHz, CDCl3): d = 7.52 (s, 1
H), 6.69 (s, 1 H), 5.99 (d, J = 1.2 Hz, 1 H), 5.98 (d, J = 1.2
Hz, 1 H), 5.70–5.63 (m, 1 H), 5.36 (dd, J = 9.9, 2.4 Hz, 1 H),
4.02 (dd, J = 5.7, 4.8 Hz, 1 H), 3.69 (d, J = 9.6 Hz, 1 H), 3.67
(d, J = 9.6 Hz, 1 H), 3.62–3.56 (m, 1 H), 2.53–2.44 (m, 1 H),
2.29–2.18 (m, 1 H), 2.07–1.70 (m, 3 H). 13C NMR (75 MHz,
CDCl3): d = 161.8, 150.5, 146.9, 135.6, 125.9, 125.3, 123.0,
107.6, 107.4, 101.6, 56.6, 42.4, 37.1, 34.2, 30.0, 25.2. IR
(neat): 2885, 1645, 1609, 1465, 1387, 1349, 1269, 1244,
1036, 933, 770, 703 cm–1. [a]D24 –111.4 (c 0.38, CHCl3).
Compound 12: 1H NMR (300 MHz, CDCl3): d = 6.61 (s, 1
H), 6.49 (s, 1 H), 5.89 (d, J = 1.2 Hz, 1 H), 5.88 (d, J = 1.2
Hz, 1 H), 4.02 (d, J = 14.1 Hz, 1 H), 3.37 (ddd, J = 9.3, 9.0,
3.6 Hz, 1 H), 3.22 (d, J = 14.1 Hz, 1 H), 2.75 (ddd, J = 11.7,
4.5, 4.5 Hz, 1 H), 2.39 (dd, J = 4.8, 4.5 Hz, 1 H), 2.25–2.11
(m, 2 H), 2.08–1.97 (m, 1 H), 1.80–1.60 (m, 3 H), 1.55–1.30
(m, 4 H). 13C NMR (75 MHz, CDCl3): d = 146.0, 145.6,
133.1, 127.3, 108.4, 106.3, 100.7, 63.0, 57.2, 53.9, 39.6,
37.5, 31.9, 30.6, 29.5, 25.4. IR (neat): 2925, 1505, 1483,
1376, 1318, 1230, 1138, 1040, 938, 867 cm–1. [a]D25 +15.0
(c 0.44, EtOH) {lit.17 [a]D20 +17.1 (c 0.25, EtOH)}. MS
(ESI+): m/z = 258 [M + H]+.
Compound (3S,4R)-10: 1H NMR (300 MHz, CDCl3): d =
7.72 (d, J = 8.1 Hz, 2 H), 7.32 (d, J = 8.1 Hz, 2 H), 5.53 (dd,
J = 17.4, 10.8 Hz, 1 H), 5.43 (ddd, J = 17.1, 10.5, 8.4 Hz, 1
H), 5.04 (dd, J = 10.5, 1.5 Hz, 1 H), 4.98 (dd, J = 17.1, 1.5
Hz, 1 H), 4.98 (d, J = 10.8 Hz, 1 H), 4.88 (d, J = 17.4 Hz, 1
H), 3.50 (dd, J = 9.9, 7.5 Hz, 1 H), 3.44 (d, J = 9.6 Hz, 1 H),
3.16 (dd, J = 9.9, 9.9 Hz, 1 H), 3.01 (d, J = 9.6 Hz, 1 H), 2.44
(s, 3 H), 2.33–2.24 (m, 1 H), 1.02 (s, 3 H). 13C NMR (75
MHz, CDCl3): d = 143.3, 139.1, 134.1, 133.8, 129.6, 127.3,
118.2, 114.2, 58.2, 53.3, 51.0, 47.0, 21.8, 21.7. IR (neat):
2965, 1346, 1155, 1094, 1052, 922, 813, 711, 663, 587 cm–1.
[a]D19 –6.5 (c 1.03, CHCl3).
(8) Analytical and semipreparative-scale HPLC were carried
out with a chiral stationary column [CHIRALCEL OD-H
(4.6 × 250 mm or 20 × 250 mm)] equipped with a UV
detector and a CD spectropolarimeter.
(9) The absolute configurations of 2b and 2c were speculated on
the basis of the similarity of the CD spectra of 2a and 2d.
(10) Enantioenriched 2 can be prepared via the fractional
crystallization of its ammonium salt with chiral carboxylic
acid, see ref. 3b.
(11) The detailed transition-state analysis of racemization by ab
initio calculation is in progress.
(12) The enantiopurity of 2a–d remains unchanged in the solid
state(crystal) at –30 °C for at least one year.
(13) Pd(II)-catalyzed Cope rearrangement, see: Overman, L. E.;
Jacobsen, E. J. J. Am. Chem. Soc. 1982, 104, 7225.
(14) The absolute stereochemistry of 10 was deduced from the
configuration of 2b and the steric course of the reactions.
(15) In general, the aza-Wittig rearrangement is considerably
slower than the corresponding oxa-Wittig rearrangement. To
enhance the reactivity of the aza-Wittig rearrangement,
several contrivances have been developed. For reviews, see:
(a) Vogel, C. Synthesis 1997, 497. (b) Tomooka, K. In The
Chemistry of Organolithium Compounds, Vol. 2;
Compound (R,R)-11d: 1H NMR (300 MHz, CDCl3): d = 7.75
(d, J = 8.1 Hz, 2 H), 7.29 (d, J = 8.1 Hz, 2 H), 5.83–5.69 (m,
2 H), 5.36–5.32 (m, 1 H), 5.07 (dd, J = 9.0, 0.9 Hz, 1 H), 5.00
(dd, J = 17.1, 0.6 Hz, 1 H), 4.54 (d, J = 9.6 Hz, 1 H), 3.92–
3.84 (m, 1 H), 2.42 (s, 3 H), 2.37–2.29 (m, 1 H), 2.12–1.88
(m, 2 H), 1.77–1.67 (m, 1 H), 1.58–1.47 (m, 1 H). 13C NMR
(75 MHz, CDCl3): d = 143.3, 138.4, 137.2, 130.2, 129.7,
127.3, 127.2, 117.6, 51.5, 41.8, 24.8, 22.8, 21.6. IR (neat):
3278, 2925, 1433, 1331, 1160, 1084, 915, 814, 709, 660
cm–1. [a]D25 –86.1 (c 1.27, CHCl3).
Compound 13: 1H NMR (300 MHz, CDCl3): d = 7.76 (d,
J = 8.1 Hz, 2 H), 7.29 (d, J = 8.1 Hz, 2 H), 5.65 (ddd, J = 9.6,
3.6, 3.3 Hz, 1 H), 5.12 (ddd, J = 9.6, 4.5, 2.1 Hz, 1 H), 4.95–
4.85 (m, 1 H), 3.79–3.62 (m, 3 H), 2.42 (s, 3 H), 2.04–1.75
(m, 5 H), 1.63–1.42 (m, 2 H), 1.36–1.23 (m, 1 H). 13C NMR
(75 MHz, CDCl3): d = 143.2, 138.3, 130.9, 129.6, 126.9,
126.4, 60.9, 51.1, 34.9, 34.2, 24.8, 24.2, 21.6. IR (neat):
3274, 2928, 1598, 1432, 1327, 1159, 1094, 1021, 915, 815,
663 cm–1. [a]D26 –153.5 (c 1.10, CHCl3).
Compound 14: 1H NMR (300 MHz, CDCl3): d = 7.69 (d,
J = 8.1 Hz, 2 H), 7.28 (d, J = 8.1 Hz, 2 H), 5.83–5.70 (m, 2
H), 3.96 (d, J = 6.9 Hz, 1 H), 3.45 (ddd, J = 14.1, 7.5, 4.5 Hz,
1 H), 3.17 (ddd, J = 9.9, 8.4, 7.5 Hz, 1 H), 2.40 (s, 3 H),
2.03–1.89 (m, 3 H), 1.80–1.49 (m, 4 H). 13C NMR (75 MHz,
Rappoport, Z.; Marek, I., Eds.; John Wiley and Sons:
Chichester, 2004, 749–828.
Synlett 2008, No. 16, 2518–2522 © Thieme Stuttgart · New York